SCHEMBL14629928

SCHEMBL14629928

COc1cc(CI)cc(C(=O)Nc2ccc(CI)cc2)c1NC(=O)c1ccc(C(=N)N2CCCC2)cc1F

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.48
LMNA P02545 2/20 0.42
ITGB3 P05106 2/20 0.39
ITGA2B P08514 2/20 0.39
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
MAPT P10636 1/20 0.38
KMT2A Q03164 3/20 0.38
MEN1 O00255 2/20 0.38
HSD11B1 P28845 1/20 0.38
KDR P35968 1/20 0.38
USP2 O75604 1/20 0.38
ABL1 P00519 2/20 0.37
RIN1 Q13671 2/20 0.37
CPT2 P23786 1/20 0.37
CPT1A P50416 1/20 0.37
CPT1B Q92523 1/20 0.37
F2 P00734 1/20 0.37
F10 P00742 1/20 0.37
KLK1 P06870 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14629927 0.99 KCNH2 (0.47) KCNH2LMNAITGB3ITGA2BNPC1
SCHEMBL14629881 0.91 LMNA (0.43) LMNANPC1RAB9AMAPTKMT2A
SCHEMBL14629865 0.90 LMNA (0.44) LMNANPC1RAB9AMAPTKMT2A
SCHEMBL14632260 0.88 KCNH2 (0.59) KCNH2F2F10
SCHEMBL14632266 0.87 KCNH2 (0.58) KCNH2F2F10
SCHEMBL14629962 0.85 KCNH2 (0.60) KCNH2F2F10
SCHEMBL14629917 0.84 KCNH2 (0.68) KCNH2F2F10
SCHEMBL14629940 0.84 F10 (0.43) KCNH2NPC1RAB9AMAPTKMT2A
SCHEMBL10179342 0.84 KCNH2 (0.62) KCNH2LMNANPC1RAB9AKMT2A
SCHEMBL10179031 0.83 KCNH2 (0.62) KCNH2LMNANPC1RAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070021472-A1 N-(5-bromo-2-pyridinyl)-(2-4-[(2-aminosulfonyl)phenyl]phenylcarbonylamino)phenylcarboxamide; potent and highly selective inhibitors; coagulation disorders; antithrombotic agents; diagnostic reagents; good bioavailability and/or solubility MILLENNIUM PHARMACEUTICALS, INC. 2007-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070021472-A1 N-(5-bromo-2-pyridinyl)-(2-4-[(2-aminosulfonyl)phenyl]phenylcarbonylamino)phenylcarboxamide; potent and highly selective inhibitors; coagulation disorders; antithrombotic agents; diagnostic reagents; good bioavailability and/or solubility F2, TFPI, PLG KCNH2 1101/4885LMNA 101/4885ITGB3 2089/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.